Professor School of Veterinary Medicine, University of California Davis Loomis, California, United States
Presentation Description / Summary: This session will discuss controversies and challenges of antimicrobial therapy in the neonatal foal, including dosing considerations for specific illnesses and organ dysfunctions. It will include the dynamic pharmacokinetic and pharmacodynamic variables often associated with critical illness. It will also review therapeutic drug monitoring (TDM) of aminoglycosides and how data can help with optimal dosing when TDM is not available. It will also discuss targeting minimum inhibitory concentrations (MICs) of bacteria commonly associated with sepsis, and increasing concerns over rising MICs and multi-drug resistant bacteria.
Learning Objectives:
1. Describe the variable and dynamic pharmacokinetic and pharmacodynamic physiology of critically ill neonatal foals
2. Describe what therapeutic drug monitoring of aminoglycosides consists of and what it tells us
3. Describe rising concerns over multi-drug resistant bacteria
4. Describe antimicrobial principles to consider for localized versus generalized sepsis
